News

Filter

Current filters:

None

Popular Filters

8080 to 8104 of 8762 results

Forest Lab’s profit slumps nearly 13%, but sales up 9%

19-10-2011

US drugmaker Forest Laboratories (NYSE: FRX) has posted disappoint results for its fiscal second quarter…

FinancialForest LaboratoriesPharmaceutical

Superior combo therapies to sustain HIV/AIDS market growth despite major patent expiries

19-10-2011

The HIV/AIDS therapeutics market is a growing therapy sector, with the USA dominating in terms of revenues.…

Anti-viralsGlobalMarkets & MarketingPatentsPharmaceutical

Early treatment with Biogen and Elan’s Tysabri reduces MS relapse rates

19-10-2011

US biotech firm Biogen Idec (Nasdaq: BIIB) and Ireland-based Elan Corp (NYSE: ELN) have released new…

Biogen IdecBiotechnologyElanImmunologicalsNeurologicalPharmaceuticalResearchTysabri

Mylan settles with Warner Chilcott over Femcon

19-10-2011

US generic drugmaker Mylan (Nasdaq: MYL) said yesterday that it, along with Famy Care, has entered into…

Femcon FeGenericsLegalMylan LaboratoriesNorth AmericaPatentsRespiratory and PulmonaryWarner Chilcott

Autistic disorder therapeutics market set to grow to $5.5 billion by 2018

19-10-2011

The autism spectrum disorder (ASD) therapeutics market was valued at $3.1 billion in 2010 and is forecast…

Markets & MarketingNeurologicalPharmaceutical

US Senators Kohl and Grassley urge “Super Committee” to encourage generic competition

19-10-2011

As the USA’s Joint Select Committee on Deficit Reduction - dubbed the “Super Committee”…

GenericsHealthcareNorth AmericaPatentsPharmaceuticalPolitics

Johnson & Johnson beats forecasts, despite profit downturn in 3rd-qtr 2011

19-10-2011

US health care giant Johnson & Johnson (NYSE: JNJ), first of the US pharma majors to report third-quarter…

FinancialJohnson & JohnsonPharmaceutical

Top EU firms increase investment in innovation, but lag behind global competitors

19-10-2011

The European Commission's 2011 EU Industrial R&D Investment Scoreboard shows that R&D investment by top…

FinancialPfizerPharmaceuticalResearchRocheSanofi

Lux Biosciences withdraws European marketing application for uveitis drug Luveniq

19-10-2011

The European Medicines Agency has been formally notified by the European subsidiary of USA-based biotech…

BiotechnologyEuropeLuveniqLux BiosciencesOphthalmicsPharmaceuticalRegulation

Flutiform review to take longer than expected, says SkyePharma

19-10-2011

UK-based SkyePharma (LSE: SKP) revealed yesterday that the review of the European Marketing Authorization…

EuropeFlutiformMundi InternationalPharmaceuticalRegulationRespiratory and PulmonarySkyepharma

Australian coalition government announces A$55 million commitment to biotechnology

18-10-2011

Australia’s Minister for Technology, Gordon Rich-Phillips this week released a new A$55 million…

Asia-PacificBiotechnologyFinancialPoliticsResearch

GlaxoSmithKline may be ready to acquire Human Genome, newspaper reports

18-10-2011

Shares of the UK’s biggest pharmaceuticals group, GlaxoSmithKline (LSE: GSK) amid revived speculation…

BenlystaBiotechnologyGlaxoSmithKlineHuman Genome SciencesMergers & AcquisitionsPharmaceutical

Angel Biotech proposes joint venture with Russia’s Materia Medica

18-10-2011

Scotland-based Angel Biotechnology (ABH: LON) saw its shares leap 20% to 0.28 pence on Monday after it…

Angel BiotechnologyBiotechnologyEuropeMateria MedicaMergers & Acquisitions

Could hypertension drugs help people with Alzheimer's?

18-10-2011

Within the next 20 years it is expected the number of people with Alzheimer's disease in the UK will…

NeurologicalPharmaceuticalResearch

Acute coronary syndrome drug market to reach around $2.8 billion in 2020

18-10-2011

The uptake of oral agents with novel modes of action such as AstraZeneca’s ADP receptor antagonist…

Cardio-vascularGlobalMarkets & MarketingPharmaceutical

Roche to boost hep C offerings with $230 million acquisition of Anadys Pharma

18-10-2011

In a further move to broaden in presence outside its current domination in the oncology sector, Swiss…

Anadys PharmaceuticalsAnti-viralsMergers & AcquisitionsPharmaceuticalRoche

UK NICE draft guidance recommends Eli Lilly’s Bydureon for type 2 diabetes

18-10-2011

The UK drugs watchdog the National Institute of Health and Clinical Excellence (NICE) today published…

BydureonDiabetesEli LillyEuropePharmaceuticalPricingRegulation

Second Indian generics deal for SA’s Litha, this one with Micro Labs

18-10-2011

In a second deal with an Indian drugmaker, South Africa’s Litha Healthcare has signed an exclusive…

Asia-PacificGenericsLicensingLitha HealthcareRest of the World

AstraZeneca and Forest initiate Ph III trials of CAZ-AVI

18-10-2011

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and USA-based Forest Laboratories (NYSE: FRX) said this…

Antibiotics and Infectious diseasesAstraZenecaavibactamCeftazidimeForest LaboratoriesPharmaceuticalResearch

Another stab at obesity drug approval, as VIVUS resubmits Qnexa to the FDA

17-10-2011

In the long-running battle to gets its obesity drug cleared for marketing, VIVUS (Nasdaq: VVUS) said…

MetabolicsNorth AmericaPharmaceuticalQnexaRegulationVivus

Pfizer updates Acura on Oxecta commercialization plans

17-10-2011

US pharma behemoth Pfizer (NYSE: PFE) has commenced executing its commercialization plan for Oxecta (oxycodone…

Acura PharmaceuticalsLicensingMarkets & MarketingNeurologicalNorth AmericaOxectaPfizerPharmaceutical

Takeda names Nycomed’s Jostein Davidsen as head of Emerging Markets

17-10-2011

Swiss drugmaker Nycomed, the near $13 billion acquisition of which was recently completed by Japan’s…

ManagementNycomedPharmaceuticalTakeda Pharmaceuticals

Daiichi Sankyo research exec points out “a lot of hype” around biomarkers

17-10-2011

Robert Beckman, executive director, clinical development oncology at Japanese drug major Daiichi Sankyo…

Daiichi SankyoOncologyPharmaceuticalResearch

8080 to 8104 of 8762 results

Back to top